CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 19, 2015, Pages 5875-5882

  Shuda, Masahiro ^a   Velásquez, Celestino ^a   Cheng, Erdong ^a   Cordek, Daniel G ^a   Kwun, Hyun Jin ^a   Chang, Yuan ^a   Moore, Patrick S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

4E BP1; Cyclin dependent kinase 1; Merkel cell; Mitosis; Small T

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 4E1RCAT; ANAPHASE PROMOTING COMPLEX; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAP BINDING PROTEIN; CAPPED RNA; CELL CYCLE PROTEIN 20; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; GUANOSINE TRIPHOSPHATE; INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4G; LIGASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MERKEL CELL POLYOMAVIRUS SMALL T PROTEIN; MIMOSINE; NOCODAZOLE; ONCOPROTEIN; RO 3306; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UVOMORULIN; VIRUS PROTEIN; CDK1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; VIRUS T ANTIGEN;

ARTICLE; BINDING SITE; CELL CYCLE ARREST; CELL LINE; CELL POPULATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERPHASE; MITOGENESIS; MITOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; CELL PROLIFERATION; CHEMISTRY; HEK293 CELL LINE; METABOLISM; NEOPLASM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE;

EUKARYOTA; POLYOMAVIRUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; HEK293 CELLS; HELA CELLS; HUMANS; INTERPHASE; MITOSIS; NEOPLASMS; NOCODAZOLE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTEIN STRUCTURE, TERTIARY; TOR SERINE-THREONINE KINASES;

EID: 84929208099     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1505787112     Document Type: Article

References (53)

1. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, translation initiation and cancer. Oncogene 25(48):6416-6422.
2. Hsieh AC, et al. (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17(3):249-261.
3. She QB, et al. (2010) 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18(1):39-51.
4. Wang X, Proud CG (2011) mTORC1 signaling: What we still don't know. J Mol Cell Biol 3(4):206-220.
5. Armengol G, et al. (2007) 4E-binding protein 1: A key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 67(16):7551-7555.
6. Sabatini DM (2006) mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 6(9):729-734.
7. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95(4):1432-1437.
8. Gingras AC, et al. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15(21):2852-2864.
9. Herbert TP, Tee AR, Proud CG (2002) The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem 277(13):11591-11596.
10. Heesom KJ, Gampel A, Mellor H, Denton RM (2001) Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1). Curr Biol 11(17):1374-1379.
11. Shang ZF, et al. (2012) 4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1. Cell Cycle 11(18):3463-3471.
12. Shin S, et al. (2014) Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 33(13):1690-1699.
13. Prescott DM, Bender MA (1962) Synthesis of RNA and protein during mitosis in mammalian tissue culture cells. Exp Cell Res 26:260-268.
14. Konrad CG (1963) Protein synthesis and Rna synthesis during mitosis in animal cells. J Cell Biol 19:267-277.
15. Coldwell MJ, et al. (2013) Phosphorylation of eIF4GII and 4E-BP1 in response to nocodazole treatment: A reappraisal of translation initiation during mitosis. Cell Cycle 12(23):3615-3628.
16. Greenberg VL, Zimmer SG (2005) Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism. Oncogene 24(30):4851-4860.
17. Feng H, Shuda M, Chang Y, Moore PS (2008) Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319(5866):1096-1100.
18. Schrama D, Ugurel S, Becker JC (2012) Merkel cell carcinoma: Recent insights and new treatment options. Curr Opin Oncol 24(2):141-149.
19. Chang Y, Moore PS (2012) Merkel cell carcinoma: A virus-induced human cancer. Annu Rev Pathol 7:123-144.
20. Spurgeon ME, Lambert PF (2013) Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. Virology 435(1):118-130.
21. Shuda M, Kwun HJ, Feng H, Chang Y, Moore PS (2011) Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest 121(9):3623-3634.
22. Shuda M, Chang Y, Moore PS (2014) Merkel cell polyomavirus-positive Merkel cell carcinoma requires viral small T-antigen for cell proliferation. J Invest Dermatol 134(5):1479-1481.
23. Kwun HJ, et al. (2015) Restricted protein phosphatase 2A targeting by Merkel cell polyomavirus small T antigen. J Virol 89(8):4191-4200.
24. Kwun HJ, et al. (2013) Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. Cell Host Microbe 14(2):125-135.
25. Verhaegen ME, et al. (2014) Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. J Invest Dermatol, 10.1038/jid.2014.446.
26. Gingras AC, et al. (1999) Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev 13(11):1422-1437.
27. Kanie T, et al. (2012) Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation. Mol Cell Biol 32(3):590-605.
28. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N (1998) 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12(4):502-513.
29. Feldman ME, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7(2):e38.
30. Tyler RK, Shpiro N, Marquez R, Eyers PA (2007) VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle 6(22):2846-2854.
31. Vassilev LT, et al. (2006) Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA 103(28):10660-10665.
32. Chung J, Kuo CJ, Crabtree GR, Blenis J (1992) Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69(7):1227-1236.
33. Magnuson B, Ekim B, Fingar DC (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441(1):1-21.
34. Vassilev LT (2006) Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1. Cell Cycle 5(22):2555-2556.
35. Pyronnet S, Pradayrol L, Sonenberg N (2000) A cell cycle-dependent internal ribosome entry site. Mol Cell 5(4):607-616.
36. Kiick KL, Saxon E, Tirrell DA, Bertozzi CR (2002) Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. Proc Natl Acad Sci USA 99(1):19-24.
37. Wang Q, et al. (2003) Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc 125(11):3192-3193.
38. Nielsen DA, Shapiro DJ (1986) Preparation of capped RNA transcripts using T7 RNA polymerase. Nucleic Acids Res 14(14):5936.
39. Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE (2001) Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3′-Omethyl)GpppG and 7-methyl (3′-deoxy)GpppG. RNA 7(10):1486-1495.
40. Cencic R, et al. (2011) Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci USA 108(3):1046-1051.
41. Mazroui R, Di Marco S, Kaufman RJ, Gallouzi IE (2007) Inhibition of the ubiquitin-proteasome system induces stress granule formation. Mol Biol Cell 18(7):2603-2618.
42. Stehelin D, Varmus HE, Bishop JM, Vogt PK (1976) DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260(5547):170-173.
43. Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278(5701):261-263.
44. Linzer DI, Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17(1):43-52.
45. Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248(4951):76-79.
46. DeCaprio JA, et al. (1988) SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54(2):275-283.
47. Chang HW, et al. (1997) Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276(5320):1848-1850.
48. Moore PS, Chang Y (1998) Antiviral activity of tumor-suppressor pathways: Clues from molecular piracy by KSHV. Trends Genet 14(4):144-150.
49. Shahbazian D, et al. (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25(12):2781-2791.
50. Wang X, et al. (2001) Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20(16):4370-4379.
51. Wilker EW, et al. (2007) 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature 446(7133):329-332.
52. Boussemart L, et al. (2014) eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 513(7516):105-109.
53. Terasima T, Tolmach LJ (1963) Growth and nucleic acid synthesis in synchronously dividing populations of HeLa cells. Exp Cell Res 30:344-362.